BioSpace News Archive

BioNTech, headquartered in Mainz, Germany, and Pfizer, based in New York City, signed a multi-year research-and-development deal to develop mRNA-based flu vaccines.

Shares of Sun Pharmaceuticals have climbed more than 3 percent this morning after the U.S. Food and Drug Administration approved its dry eye treatment Cequa (cyclosporine ophthalmic solution) 0.09 percent.

Regeneron’s fasinumab hit the mark in a late-stage study assessing patients with chronic pain from osteoarthritis (OA) of the knee or hip. At 16 weeks patients experienced significantly less pain and also showed significantly improved functional ability from baseline.

Yet another company is launched to focus on longevity and diseases of aging. The Buck Institute for Research on Aging, Insilico Medicine, an artificial intelligence (AI) company with offices and resources in the U.S., Belgium, Russia, the UK, Taiwan and Korea, and Juvenescence, also a human longevity company, founded Napa Therapeutics to develop drugs against a novel aging-related target.

Maria Fardis, chief executive officer of Iovance Biotherapeutics, sees tumor infiltrating lymphocyte (TIL) therapies as the best immunotherapy option to treat solid cancers.

You Never Have a Second Chance to make a Good First Impression! When you are applying for a job online your resume is the first impression an organization will have of you.

As investigations into China’s major vaccine scandals continue, a number of top regulators and politicians have been fired as a result. Bi Jingquan, former head of China’s Drug Administration, resigned. Two deputy Chinese provincial governors and one mayor were also fired by the Community Party over the scandal.

Genentech is slashing 223 jobs at its South San Francisco headquarters, according to a Worker Adjustment and Retraining Notification posted on a California state government website. The layoffs will go into effect on Aug. 31, according to the WARN posting.

As gene therapies have become reality, the U.S. government is removing some special regulations that had been set up long ago over concerns of exotic safety risks.

Biohaven Pharma, headquartered in New Haven, Conn., announced positive data from a proof-of-concept trial for its BHV-0223 in social anxiety and public speaking anxiety disorders.